StockGuide AI
Track Stocks
EN RU ES
Cidara Therapeutics

Cidara Therapeutics

Price: 221.38

Company and Business Model

Cidara Therapeutics is a biotechnology company focused on developing innovative therapeutics for serious fungal infections and other diseases. Its core products include the antifungal agent rezafungin, which is in clinical development for treating invasive fungal infections. The company primarily generates revenue through research and development collaborations and potential future product sales.

Investment Profile

The investment profile of Cidara Therapeutics is more aligned with growth investors due to its focus on developing novel therapies in a specialized market. The company currently does not provide dividends, and its financial performance indicates a higher risk profile. Investors should consider the potential for significant returns against the backdrop of inherent volatility in the biotech sector.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-11.78 Risk
20d volatility
0.1% stable
FMP / FinFeed data updated: 2026-06-06
Reco: Sell Potential: 30 Risk: 80 Updated: 2026-06-11 05:16
How recommendation works
Why AI thinks so:
Weak fundamentals and high volatility raise significant concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-08 15:06 — Sell Weak fundamentals and high volatility raise significant concerns.
2026-05-08 05:21 Hold Hold Компания показывает значительный рост за последние 60 и 120 дней, но отрицательный EPS и высокая волатильность указывают на высокий риск. Рекомендуется удерживать акции до получения более стабильных финансовых показателе
2026-03-11 05:49 Sell Hold Компания демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и высокая волатильность указывают на риски. Рекомендуется удерживать акции до получения более стабильных финансовых результатов.
Analyst forecasts
Date Analyst Action Target Price Then
2025-11-14 21:13 RBC Capital Rating Downgraded — → 221.5 217.71
2025-10-09 14:44 H.C. Wainwright Target Raised 110 → 150 108.18
2025-10-03 09:40 JMP Securities Target Raised 153 → 173 98.5